hydrALAZINE HCl Tablets, USP, 10 mg, 100 Tablets per carton (10x10 blister packs), Rx only, Distr...
FDA Drug Recall #D-0653-2022 — Class II — February 24, 2022
Recall Summary
| Recall Number | D-0653-2022 |
| Classification | Class II — Moderate risk |
| Date Initiated | February 24, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | The Harvard Drug Group |
| Location | Livonia, MI |
| Product Type | Drugs |
| Quantity | 5,953 cartons |
Product Description
hydrALAZINE HCl Tablets, USP, 10 mg, 100 Tablets per carton (10x10 blister packs), Rx only, Distributed by: MAJOR PHARMACEUTICALS, Livonia, MI 48152 USA. NDC # 0904-6440-61
Reason for Recall
Failed Impurities/Degradation Specifications: Out of specification result obtained during routine stability testing for Impurities.
Distribution Pattern
Nationwide within USA
Lot / Code Information
Lot #: T03755, T03756, Exp. Date 03/2023
Other Recalls from The Harvard Drug Group
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0878-2023 | Class II | Tramadol Hydrochloride Tablets, USP 50 mg, Unit... | Jun 16, 2023 |
| D-0570-2023 | Class III | Gabapentin Tablets, USP 600 mg, packaged in Car... | Apr 24, 2023 |
| D-0432-2023 | Class II | Carbidopa and Levodopa Tablets, USP 25 mg/100 m... | Feb 23, 2023 |
| D-0649-2022 | Class II | PALIPERIDONE EXTENDED-RELEASE TABLETS, 9 mg, 10... | Feb 28, 2022 |
| D-0807-2021 | Class II | Carbamazepine 200mg Tablets, USP, 200 mg, 100 C... | Aug 6, 2021 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.